Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis.

Autor:	Hariharan NN; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada., Patel K; School of Medicine, University of Ottawa, Ottawa, ON, Canada., Sikder O; McMaster University, Hamilton, ON, Canada., Perera KS; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton, ON, Canada., Diener HC; University of Duisburg-Essen, Duisburg, Germany., Hart RG; McMaster University, Hamilton, ON, Canada.; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton, ON, Canada., Eikelboom JW; McMaster University, Hamilton, ON, Canada.; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton, ON, Canada.
Jazyk:	angličtina
Zdroj:	European stroke journal [Eur Stroke J] 2022 Jun; Vol. 7 (2), pp. 92-98. Date of Electronic Publication: 2022 Feb 11.
DOI:	10.1177/23969873221076971
Abstrakt:	Purpose: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of direct oral anticoagulation (DOAC) compared with antiplatelet therapy for secondary stroke prevention in adult patients with embolic stroke of undetermined source (ESUS). Method: We searched major databases (Embase, MEDLINE, CINAHL, CENTRAL, and Web of Science) for RCTs published until March 2021. The primary outcome was recurrent stroke, and the main safety outcomes were major bleeding and clinically relevant non-major bleeding (CRNB). We assessed risk of bias using the Cochrane Risk of Bias tool. We used a random-effects model to determine pooled risk ratios and 95% confidence intervals in the datasets and key subgroups. Findings: Our search identified two RCTs, involving a total of 12,603 patients with ESUS. Anticoagulation with dabigatran or rivaroxaban compared with aspirin did not reduce the risk of recurrent stroke (RR, 0.96 [0.76-1.20]) or increase major bleeding (RR, 1.77 [0.80-3.89]) but significantly increased the composite of major or clinically relevant non-major bleeding (RR, 1.57 [1.26-1.97]). Prespecified subgroup analysis demonstrated consistent results according to age and sex. Additional post-hoc subgroup analyses demonstrated consistent results according to prior stroke and presence of a patent foramen ovale but suggested that DOACs reduced recurrent stroke in patients with an estimated glomerular filtration rate (eGFR) <50 and 50-80 ml/min but not in those with eGFR >80 ml/min (interaction P = 0.0234). Discussion/conclusion: Direct oral anticoagulations are not more effective than aspirin in preventing stroke recurrence in patients with ESUS and increase bleeding. Registration: PROSPERO ID: CRD42019138593. Competing Interests: Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: In the last 3 years, HCD received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Novo-Nordisk, Pfizer, Portola, and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. HCD received research grants from the German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-Nixdorf Foundation. JWE has received honoraria and/or research support from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Janssen, Pfizer, Portola, and WebMD Global. (© European Stroke Organisation 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu